Biomarker technology
Total Trials
24
As Lead Sponsor
17
As Collaborator
7
Total Enrollment
4,005
NCT00149292
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 23, 2005
Completion: Jul 17, 2006
NCT00845026
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
Start: Mar 31, 2009
Completion: Dec 31, 2010
NCT01052103
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
Start: Jan 31, 2010
Completion: Jun 30, 2012
NCT01125358
A Study in Schizophrenic Patients
Start: May 31, 2010
Completion: Sep 30, 2012
NCT01307800
A Study of LY2140023 in Patients With Schizophrenia
Phase: Phase 3
Start: Mar 31, 2011
NCT01328093
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
Start: Apr 30, 2011
Completion: Oct 31, 2012
NCT01354353
A Study of Safety and Tolerability in Subjects With Schizophrenia
Phase: Phase 1
Start: May 31, 2011
Completion: Mar 31, 2012
NCT01452919
A Physical Dependence Study in Schizophrenia
Start: Nov 30, 2011
NCT01475136
A Study of LY2140023 in Hepatically-Impaired Participants
Completion: Dec 31, 2012
NCT01591330
A Study of LY2140023 in Healthy Males and Females
Start: Apr 30, 2012
Completion: Aug 31, 2012
NCT01606436
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
Start: Jun 30, 2012
NCT01609218
A Study of LY2140023 in Healthy Participants
NCT01637142
Start: Jul 31, 2012
Completion: Jul 31, 2012
NCT01659177
Start: Aug 31, 2012
NCT03263026
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Start: Mar 20, 2018
Completion: Aug 11, 2022
NCT03776071
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Start: Dec 16, 2020
Completion: Feb 29, 2024
NCT05113771
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
Start: Jun 29, 2022
Completion: Mar 5, 2024
NCT05802264
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
Role: Collaborator
Start: Mar 21, 2023
Completion: Dec 31, 2025
NCT06132256
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Start: Dec 11, 2023
Completion: Nov 30, 2026
NCT06329401
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Start: Apr 3, 2024
Completion: Apr 30, 2026
NCT06264388
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Start: May 1, 2024
Completion: May 1, 2034
NCT06496607
A Study to Evaluate Solriktug in Adult Participants With Asthma
Start: Jul 26, 2024
NCT06496620
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Start: Aug 14, 2024
Completion: Oct 31, 2026
NCT06504381
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Phase: Phase 1/2
Start: Jan 8, 2025
Completion: Jan 31, 2042
Loading map...